Toward orthopoxvirus countermeasures: A novel heteromorphic nucleoside of unusual structure

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4052-4054

  Fan, Xuesen ^a   Zhang, Xinying ^a   Zhou, Longhu ^a   Keith, Kathy A ^b   Prichard, Mark N ^b   Kern, Earl R ^b   Torrence, Paul F ^a  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AMINO 3 CYANO 5 OXO 5,6,7,8 TETRAHYDRO 4H CHROMEN 4 YL) 1 (2 DEOXYPENTOFURANOSYL)PYRIMIDINE 2,4(1H,3H) DIONE; ANTIVIRUS AGENT; CIDOFOVIR; IDOXURIDINE; NUCLEOSIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; COWPOX VIRUS; NONHUMAN; NUCLEIC ACID STRUCTURE; ORTHOPOXVIRUS; PHOSPHORYLATION; VACCINIA VIRUS;

ANTIVIRAL AGENTS; BENZOPYRANS; CELL SURVIVAL; CELLS, CULTURED; COWPOX VIRUS; FIBROBLASTS; HUMANS; ORTHOPOXVIRUS; PYRIMIDINE NUCLEOSIDES; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE KINASE; VACCINIA VIRUS;

EID: 33745833395     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060404n     Document Type: Article

References (46)

1. Bray, M. Viral Bioterrorism and Antiviral Countermeasures. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; p 17.
2. Torrence, P. F. Introduction: Pestilence, Plague, Bioterrorism. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats: Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; p 3.
3. Tseng, C. K. Overview of Antiviral Drug Discovery and Development. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; p 31.
4. Kern, E. R. Discovery and Development of New Antivirals for Smallpox. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; p 331.
5. De Clercq, E. Antiviral Drug Targets and Strategies for Emerging Viral Disease and Bioterrorism Threats. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; John Wiley & Sons: New York, 2005; p 83.
6. Bradbury, J. Orally available cidofovir derivative active against smallpox. Lancet 2002, 359 (9311), 1041.
7. Buller, R. M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J. R.; Hostetler, K. Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318 (2), 474.
8. Ciesla, S. L.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hostetler, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59 (3), 163.
9. Aldern, K. A.; Ciesla, S. L.; Winegarden, K. L.; Hosteller, K. Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]-cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63 (3), 678.
10. Keith, K. A.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 2004, 48 (5), 1869.
11. Byrd, C. M.; Bolken, T. C.; Mjalli, A. M.; Arimilli, M. N.; Andrews, R. C.; Rothlein, R.; Andrea, T.; Rao, M.; Owens, K. L.; Hruby, D. E. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol. 2004, 78 (22), 12147.
12. Yang, G.; Pevear, D. C.; Davies, M. H.; Collett, M. S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J. W.; Baker, R. O.; Buller, R. L.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005, 79 (20), 13139.
13. Yang, H.; Kim, S. K.; Kim, M.; Reche, P. A.; Morehead, T. J.; Damon, I. K.; Welsh, R. M.; Reinherz, E. L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 2005, 115 (2), 379.
14. Fauci, A. S.; Challberg, M. D. Host-based antipoxvirus therapeutic strategies: turning the tables. J. Clin. Invest. 2005, 115 (2), 231.
15. Reeves, P. M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M. B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11 (7), 731.
16. Fan, X.; Zhang, X.; Zhou, L., Keith, K. A.; Kern, E. R.; Torrence, P. F. A Pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity. Bioorg. Med. Chem. Lett. , in press.
17. Fan, X.; Zhang, X.; Zhou, L.; Keith, K. A.; Kern, E. R.; Torrence, P. F. 5-(Dimethoxymethyl)-27prime;deoxyuridine: A novel gem diether nucleoside with anti-orthopoxvirus activity. J. Med. Chem., in press.
18. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screening 2004, 7 (5), 473.
19. Horton, D. A.; Bourne, G. T.; Smythe, M. L. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Mol. Diversity 2002, 5 (4), 289.
20. De Clercq, E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004, 2 (9), 704.
21. Muller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today 2003, 8 (15), 681.
22. Pulici, M.; Cervi, G.; Martina, K.; Quartieri, F. Use of multicomponent, domino, and other one-pot syntheses on solid phase: powerful tools for the generation of libraries of diverse and complex compounds. Comb. Chem. High Throughput Screening 2003, 6 (7), 693.
23. Dondoni, A.; Massi, A. Decoration of dihydropyrimidine and dihydropyridine scaffolds with sugars via Biginelli and Hantzsch multicomponent reactions: an efficient entry to a collection of artificial nucleosides. Mol. Diversity 2003, 6 (3-4), 261.
24. Shaabani, A.; Bazgir, A.; Bijanzadeh, H. R. A reexamination of Biginelli-like multicomponent condensation reaction: one-pot regioselective synthesis of spiro heterobicyclic rings. Mol. Diversity 2004, 8 (2), 141.
25. Bharadwaj, A. R.; Scheidt, K. A. Catalytic multicomponent synthesis of highly substituted pyrroles utilizing a one-pot Sila-Stetter/Paal-Knorr strategy. Org. Lett. 2004, 6 (14), 2465.
26. Ono, A.; Okamoto, T.; Inada, M.; Nara, H.; Matsuda, A. Nucleosides and nucleotides. 131. Synthesis and properties of oligonucleotides containing 5-formyl-2′-deoxyuridine. Chem. Pharm. Bull. (Tokyo) 1994, 42 (11), 2231.
27. Park, J. S.; Chang, C. T.; Schmidt, C. L.; Golander, Y.; De Clercq, E.; Descamps, J.; Merles, M. P. Oxime and dithiolane derivatives of 5-formyl-2′-deoxyuridine and their 5′-phosphates: antiviral effects and thymidylate synthetase inhibition. J. Med. Chem. 1980, 23 (6), 661.
28. Kampf, A.; Pillar, C. J.; Woodford, W. J.; Merles, M. P. Synthesis of 5-substituted 2′-deoxyuridines. J. Med. Chem. 1976, 19 (7), 909.
29. Selway, J. W. Antiviral activity of flavones and flavans. Prog. Clin. Biol Res. 1986, 213, 521.
30. Cheng, H. Y.; Lin, C. C.; Lin, T. C. Antiviral properties of prodelphinidin B-2 3′-O-gallate from green tea leaf. Antiviral Chem. Chemother. 2002, 13, (4), 223.
31. Bauer, D. J.; Selway, J. W.; Batchelor, J. F.; Tisdale, M.; Caldwell, I. C.; Young, D. A. 4′,6-Dichloroflavan (BW683C), a new antirhinovirus compound. Nature 1981, 292 (5821), 369.
32. Iwashima, M.; Mori, J.; Ting, X.; Matsunaga, T.; Hayashi, K.; Shinoda, D.; Saito, H.; Sankawa, U.; Hayashi, T. Antioxidant and antiviral activities of plastoquinones from the brown alga Sargassum micracanthum, and a new chromene derivative converted from the plastoquinones. Biol. Pharm. Bull. 2005, 28 (2), 374.
33. Singh, K.; Singh, J.; Singh, H. A synthetic entry into fused pyran derivatives through carbon transfer reactions of 1,3-oxazinanes and oxazolidines with carbon nucleophiles. Tetrahedron 1996, 52 (45), 14273.
34. Kern, E. R. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003, 57(1-2), 35.
35. Roy, A.; Schneller, S. W.; Keith, K. A.; Hartline, C. B.; Kern, E. R. The 4′,4′-difluoro analog of 5′-noraristeromycin: A new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus. Bioorg. Med. Chem. 2005, 13, 4443.
36. Keith, K. A.; Hitchcock, M. J.; Lee, W. A.; Holy, A.; Kern, E. R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 2003, 47 (7), 2193.
37. Pirrung, M. C.; Pansare, S. V.; Sarma, K. D.; Keith, K. A.; Kern, E. R. Combinatorial optimization of isatin-β-thiosemicarbazones as antipoxvirus agents. J. Med. Chem. 2005, 48 (8), 3045.
38. Ali, A. N.; Turner, P. C.; Brooks, M. A.; Moyer, R. W. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology 1994, 202 (1), 305.
39. De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23 (10), 456.
40. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55 (1), 1.
41. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2001, 14 (2), 382.
42. Hruby, D. E.; Ball, L. A. Cell-free synthesis of enzymatically active vaccinia virus thymidine kinase. Virology 1981, 113 (2), 594.
43. Black, M. E.; Hruby, D. E. Identification of the ATP-binding domain of vaccinia virus thymidine kinase. J Biol Chem 1990, 265 (29), 17584.
44. Black, M. E.; Hruby, D. E. Quaternary structure of vaccinia virus thymidine kinase. Biochem. Biophys. Res. Commun. 1990, 169 (3), 1080.
45. Black, M. E.; Hruby, D. E. Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding. J. Biol. Chem. 1992, 267 (10), 6801.
46. Black, M. E.; Hruby, D. E. A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase. J. Biol. Chem. 1992, 267(14), 9743.